

1 Performance evaluation of the Xpert MTB/XDR test for the detection of drug
2 resistance to *Mycobacterium tuberculosis* among people diagnosed with tuberculosis
3 in South Africa

4
5 Shaheed Vally Omar^a, Gail Louw^{b,c}, Farzana Ismail^a, Xiaohong Liu^c, Dumsani
6 Ngcamu^a, Thabisile Gwala^a, Minty van der Meulen^a, Lavania Joseph^a

7 ^aCentre for Tuberculosis, National TB Reference Laboratory, National Institute for
8 Communicable Diseases a division of the National Health Laboratory Service,
9 Johannesburg, South Africa

10 ^bCepheid (PTY) LTD, Johannesburg, South Africa

11 ^cCepheid, Sunnyvale, California, USA

12

13

14 Corresponding author: shaheedvo@nicd.ac.za

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

35 **Abstract**

36

37 Background: Tuberculosis (TB) remains a significant public health concern in South
38 Africa, with high incidence rates and a growing burden of drug-resistant TB. This
39 study aimed to assess the diagnostic performance of the Xpert MTB/XDR test, a
40 novel molecular assay, for detecting drug resistance in TB patients using archived
41 sputum sediments.

42

43 Methods: The study involved a comprehensive analysis of 322 samples collected
44 from presumptive TB patients between 2016 - 2019 across South Africa, previously
45 characterized by phenotypic and genotypic methods. The Xpert MTB/XDR test was
46 evaluated for its ability to detect resistance to isoniazid (INH), ethionamide (ETH),
47 fluoroquinolones (FLQ), and second-line injectable drugs (SLID) compared to
48 phenotypic drug susceptibility testing (pDST) and whole-genome sequencing (WGS).
49 The Xpert MTB/RIF Ultra and G4 tests were performed to determine agreement with
50 this test for TB detection.

51

52 Findings: The Xpert MTB/XDR test performance showed excellent sensitivity and
53 specificity for detecting *Mycobacterium tuberculosis* (*M. tuberculosis*), with a
54 sensitivity of 98.3% and specificity of 100% compared to culture. The sensitivities
55 using a composite reference standard, pDST and sequencing, were over 90% for
56 INH, FLQ, AMK, KAN, and CAP resistance, meeting the WHO target product profile
57 criteria for this class. A lower sensitivity of 65.9% for ETH resistance was observed,
58 driven by the limited targets covered by the assay.

59

60 Interpretation: The Xpert MTB/XDR test offers a promising solution for the rapid
61 detection of drug-resistant TB in South Africa. It could significantly enhance TB
62 control efforts in this setting and contribute to improved patient care and
63 management.

64

65

66 Keywords: drug-resistant, TB, molecular, XDR, diagnostic

67

68

69

70 **Introduction**

71

72 Progress in achieving the 2018 UN High-Level Meeting targets has been
73 exceptionally poor for multidrug-resistant (MDR)/Rifampicin Resistant (RR)
74 tuberculosis (TB) with only 55% of the target achieved between 2018-2022 (1). In a
75 recent commentary on diagnostics for TB, the authors succinctly summarized the
76 situation as "... if we cannot find TB, we cannot treat TB. And if we cannot treat TB,
77 we cannot end TB", highlighting the central role of diagnostics to address the gaps
78 (2).

79

80 Over the past decade, South Africa has made significant progress towards the
81 prevention and management of TB disease and drug-resistant TB since adopting the
82 WHO's recommended diagnostic technologies and therapies. South Africa is now
83 one of six high-burden countries that achieved the 2020 End TB Strategy milestones
84 of a 20% reduction in TB incidence rates (3) and has sustained this milestone in
85 2021 (4). It is ranked as one of the WHO's top 30 high-burden countries MDR/RR-TB
86 (4) and has a disproportionate burden on the African continent, with 32%
87 (6781/21402) of the laboratory-confirmed cases reported from this country alone (1).

88

89 One of the key elements for meeting the End TB strategy (5), is the recommendation
90 to use WHO-endorsed rapid molecular tests, such as the Xpert[®] MTB/RIF ("G4")
91 (Cepheid, Sunnyvale, CA, USA) for the diagnosis of TB and the detection of
92 rifampicin (RIF) resistance in patients presumptive of TB rather than smear
93 microscopy (6) and was fully implemented in 2013 with a subsequent transition to
94 Xpert[®] MTB/RIF Ultra ("Ultra") in 2017.

95

96 Another target set in the WHO End TB Strategy is for all MDR/RR-TB patients to be
97 tested for fluoroquinolone (FQ) resistance. In 2022, only 50% of all MDR/RR-TB
98 patients were tested globally (1). The Bruker-Hain GenoType MTBDR*plus* and
99 GenoType MTBDR*s*/ line probe assays (LPAs) and phenotypic drug susceptibility
100 test (DST) based where genotypic methods are not available have been
101 implemented nationally. However, these assays require specialized facilities and it
102 can take between 1-4 weeks for results to be available (7, 8).

103

104 An important priority highlighted by WHO has been for a TB DST that is fast, with low
105 technical skill and minimal infrastructure requirements (9). In response, Cepheid
106 announced the release of the Xpert[®] MTB/XDR test in July 2020, a test capable of
107 detecting resistance using melt curve analysis by targeting associated mutations to
108 isoniazid (INH), ethionamide (ETH), fluoroquinolones (FLQ), and second-line
109 injectable agents (SLID), such as kanamycin (KAN), amikacin (AMK) and
110 capreomycin (CAP) (10). The WHO have since endorsed the MTB/XDR test as a low
111 complexity molecular sputum-based reflex test for the detection of resistance to
112 these drugs in confirmed *M. tuberculosis* positive specimens (6). The test targets
113 resistance conferring mutations in the *katG* and *fabG1* genes, *ahpC-oxyR* intergenic
114 region and *inhA* promoter for INH; *inhA* promoter mutations only for ETH resistance;
115 the *gyrA* and *gyrB* quinolone resistance determining regions (QRDR) for FLQ; and
116 the *rrs* gene and the *eis* promoter region for SLID. It reports low-level resistance to
117 INH and FLQ and also calls resistance to select SLID base on mutations detected.

118

119 The main study that assessed the clinical performance of the Xpert MTB/XDR test
120 was conducted at 2 study sites (South Africa and China), however the data
121 presented in this manuscript is focused on the South Africa data set only.

122

123 This study aimed to evaluate the performance of the Xpert MTB/XDR test to detect
124 drug resistance using phenotypic DST and whole genome sequencing (WGS)
125 restricted to test targets as the reference standard and success rate of the assay
126 compared to the G4 and Ultra test.

127

128 **Materials and Methods**

129 **Ethics**

130 The study was conducted at the Centre for Tuberculosis, National TB Reference
131 Laboratory at the National Institute for Communicable Diseases a division of the
132 National Health Laboratory Service in Johannesburg, South Africa. Ethical approval
133 M160667 for this study was obtained from the University of the Witwatersrand,
134 Johannesburg Human Research Ethics Committee.

135

136 **Sample Eligibility Criteria**

137 Archived sputum sediments, prepared from sputum specimens collected between 29
138 November 2016 to 20 June 2019 from people with presumptive TB, representative of
139 all nine provinces in South Africa, were used in this study. These samples were
140 characterized by phenotypic and genotypic methods and stored at -70°C.

141

142 *M. tuberculosis* positive and *M. tuberculosis* negative specimens were included for
143 evaluation if a minimum volume of 1mL frozen sputum sediment was available for
144 testing (11). For *M. tuberculosis* positive specimens, documented results for smear
145 microscopy, positive culture result on the BD BACTEC Mycobacterial Growth
146 Indicator Tube 960 (MGIT) platform (BD Biosciences, Sparks, MD, USA) and/or
147 Lowenstein Jensen (LJ) media were required. In addition, pDST results for isoniazid,
148 ethionamide, amikacin, kanamycin, capreomycin and moxifloxacin/levofloxacin on
149 the MGIT platform; sequencing results for *katG*, *inhA* promoter, *fabG1*, *oxyR-ahpC*
150 intergenic region, *gyrA*, *gyrB*, *rrs* and *eis* promoter; and G4 or Ultra test results were
151 also required.

152

153 For *M. tuberculosis* negative specimens, documented results indicating negative
154 culture result on MGIT and/or LJ media was required. Specimens that were
155 previously thawed were excluded from the study.

156

157 **Specimen Processing Procedures**

158 Concentrated sediments were prepared from induced or expectorated sputum and
159 subsequently stored at -70°C. These specimens were assigned a unique de-
160 identified specimen ID by a third-party individual not actively involved in the study.
161 Subsequently, the specimens were decontaminated using a commercial
162 NaLC/NaOH kit, Alphatec NAC-PAC™ Red (Alpha-Tec Systems, Inc, Vancouver,
163 WA, USA), with a final concentration of 1.5% sodium hydroxide as per manufactures
164 instruction. Two drops of the sediment were used to prepare a smear for Auramine-
165 O staining and were graded in accordance with Global Laboratory Initiative
166 Guidelines (12).

167

168 A 500µL aliquot of the sediment was inoculated into a MGIT tube and incubated at
169 37°C in the MGIT 960 system (BD Biosciences, Sparks, MD, USA), until the culture
170 flagged positive or 42 days to a negative result as per the manufacturers instruction.

171 The MGIT positive cultures were confirmed to be MTB complex by antigen testing
172 (TBCheck, BD, Sparks, USA) and were inspected for contamination by visual
173 observations, Ziehl Neelsen (ZN) staining and on blood agar prior to performing
174 pDST.

175

176 **Reference method testing (pDST and WGS)**

177 The MGIT 960 platform and BD Epicentre TBeXiST module (BD Biosciences,
178 Sparks, MD, USA) was used to perform pDST as previously described (13) which
179 included, INH, ETH, FLQ (moxifloxacin(MXF), levofloxacin (LEV) and ofloxacin
180 (OFL)) and SLID (AMK, KAN and CAP). Testing was performed for all MTB/XDR
181 drug targets using the 2018 updated WHO recommended critical concentrations
182 (14). Whole genome sequencing (WGS) and variant analysis was performed as
183 previously described (15).

184

185 **Specimen testing:**

186 **Xpert MTB/RIF; Xpert MTB/RIF ULTRA and Xpert MTB/XDR test**

187 Sediments were thawed at room temperature prior to testing and were randomly
188 assigned for processing on either the G4 or Ultra tests using the GeneXpert 6-colour
189 module system (Cepheid, Sunnyvale, USA). All sediments were tested on the
190 MTB/XDR test on the GeneXpert 10-colour module system.

191

192 Briefly, a 1,2mL aliquot of sediment was transferred to a 15mL conical screw-cap
193 tube and the sample reagent (SR) was added at a 1:3 ratio. The SR-sample mix was
194 homogenized at room temperature by vigorous shaking 10-20 times and incubated
195 for 10 minutes, followed by vigorous shaking for 10-20 times before further
196 incubation for 5 minutes. The SR-sample mix was then used to load either the G4 or
197 Ultra tests and the MTB/XDR test in accordance with the manufacturer's instructions
198 using the appropriate GeneXpert system. If an "ERROR", "INVALID" or "NO
199 RESULT" result was obtained by specimen testing, the specimen was re-tested once
200 if sufficient specimen was available. If the re-test result was also non-determinant,
201 the specimen was reported as such.

202

203 **Discrepant result resolution**

204 Discrepant results were defined as specimens where the MTB/XDR test and either
205 pDST or sequencing results were not in agreement. These discrepant results were
206 categorized as either a false positive result, which indicates a positive MTB/XDR test
207 result with a negative pDST/or sequencing result or a false negative result, which
208 indicates a negative MTB/XDR test result with a positive pDST/ sequencing result.
209 Specimens with discrepant results were investigated as follows: a) the specimen was
210 re-tested on the Xpert MTB/XDR test, if sufficient volume remained; b) the specimen
211 was tested using either sequencing or pDST that detected the targets that were not
212 in agreement; c) standard of care data associated with the specimen were reviewed
213 to determine the absence or presence of target mutations associated with specific
214 drug resistance and d) the site confirmed that the data from source document
215 matched the data captured electronically.

216

217 **Performance Analysis**

218 Clinical performance of MTB/XDR test was evaluated using the following outcome
219 measures: 1) the positive percentage agreement (PPA) and negative percentage
220 agreement (NPA) for *M. tuberculosis* detection against G4 or Ultra, 2) sensitivity and
221 specificity for *M. tuberculosis* detection using MGIT culture as the reference
222 standard; and 3) sensitivity and specificity compared to pDST (for FLQ, the final
223 result was generated considering all drugs tested for this evaluation) and sequencing
224 as reference standard independently and in combination as a composite reference
225 for resistance detection of INH, ETH, FLQs and SLID. The composite reference test
226 results were categorized as “Resistant” if either pDST or Sequencing results were
227 “Resistant”; “Susceptible” if both pDST and sequencing were “Susceptible”. Analysis
228 was performed using RStudio Team (2020) (RStudio: Integrated Development for R.
229 RStudio, PBC, Boston, MA) and the 95% confidence intervals were determined
230 using the Wilson score methods.

231

232 We also assessed the ability of the MTB/XDR test to: 1) identify low levels of
233 resistance to INH and FLQ (MXF) based on the detection of resistance causing
234 mutations which typically result in borderline minimal inhibitory concentration (MIC)
235 values that are close to the breakpoint drug concentration used in phenotypic
236 resistance testing; 2) identify resistance to KAN only, KAN and AMI, or cross-

237 resistance to all three SLID and, 3) identify non-determinate rates. Non-determinate
238 test results were excluded from the performance analysis.

239

240

241

242 **Results**

243 **Specimen characteristics**

244 A total of 324 specimens were eligible for inclusion, of these 2 were excluded due to
245 insufficient specimen volume (Figure 1). The final data analysis was done on 322
246 specimens which comprised of 46.0% females, 50.3% males and 3.7% of the
247 specimens with unknown sex (Table 1). Additionally, the median age was 37 years
248 (13 – 85) among individuals who had specimens included (Table 1). As shown in
249 Table 1, a positive MGIT culture result was obtained in 92.2% (297/322) of
250 specimens with 74.4% smear positive. A total of 100 specimens were tested on the
251 G4 test, 86.0% (86/100) were MTB positive and 74.4% (64/86) of these were RIF
252 resistant (Table 1, Figure 1). Additionally, 222 specimens were tested on the Ultra
253 test, with a positive result obtained for 91.9% (204/222) of which 30.4% (62/204)
254 were RIF resistant, 68.6% (140/204) RIF sensitive and 1% (2/204) RIF indeterminate
255 (Table 1, Figure 1). An MTB Trace detected result was obtained in 1.8% (4/222) of
256 specimens tested on the Ultra test (Table 1, Figure 1). Overall, 8.7% (28/322) of the
257 specimens were negative by the G4 and Ultra tests (Table 1, Figure 1).

258

259 **Diagnostic performance of MTB/XDR test for the detection of *M. tuberculosis***

260 The sensitivity of the MTB/XDR test for the detection of *M. tuberculosis* in smear
261 positive, smear negative and overall was 99.5% (95%CI: 97.5 - 99.9), 94.7%
262 (95%CI:87.2 - 97.9) and 98.3% (95%CI: 96.1, 99.3). The specificity was 100% (95%
263 CI: 86.7 – 100) (Table 2).

264

265 The PPA and NPA for MTB/XDR in *M. tuberculosis* detection relative to the G4 test
266 were 98.8% (95%CI: 93.7-99.8) and 100.0% (95%CI: 78.5-100.0), respectively
267 (Table 2). In this instance, the MTB/XDR test failed to detect one sample, with a
268 scant microscopy grading, identified as positive (i.e. MTB detected) by the G4 test.
269 Similarly, the PPA and NPA for MTB/XDR in *M. tuberculosis* detection relative to the
270 Ultra test was 99.5% (95%CI: 97.3-99.9) and 100.0% (95%CI: 78.5-100.0),

271 respectively (Table 2). A smear negative sample identified as MTB Trace Detected
272 by the Ultra test was not detected by the MTB/XDR test.

273

274

275

276 **Non-determinate rate**

277 The initial non-determinate rate (ND) observed for the MTB/XDR test was 3.1%
278 (10/322) (Data not shown). Of these 0.6% were due to “No Result” and 2.5% due to
279 “Error” results obtained by the MTB/XDR test. Repeat testing of these specimens
280 rendered a valid result with final ND rate of 0% (Data not shown).

281

282 **Diagnostic performance of the MTB/XDR test for drug resistance prediction**

283 The diagnostic performance of the MTB/XDR test against pDST, sequencing and the
284 composite reference test for all drugs are shown in Figure 2, 3 and 4, respectively.

285

286 **Isoniazid & Ethionamide**

287 Results for the test and reference standard for INH were available for 291 samples.
288 The sensitivity and specificity to detect INH resistance compared to pDST was
289 90.7% (95% CI: 84.8 – 94.5) and 98.7% (95% CI: 95.3 - 99.6), respectively (Figure
290 2) while compared to WGS was 98.5% (95% CI: 94.6 – 99.6) and specificity of
291 99.4% (95% CI: 96.6 – 99.9) respectively (Figure 3). Using a composite reference,
292 the sensitivity was 90.1% (95% CI: 84.1 – 94.0) and a specificity of 99.3% (95% CI:
293 96.3 – 99.9) (Figure 4).

294

295 The prediction of low level of INH resistance using sequencing as reference test was
296 100% (Supplementary Table 2). The majority (95.8%; 23/24) of samples with low
297 level INH resistance detected harbored the C-15T mutation in the *inhA* promoter and
298 4.2% (1/24) samples showed the T-8A mutation in the *inhA* promoter
299 (Supplementary Table 2).

300

301 Ethionamide (ETH) resistance prediction on the MTB/XDR test is based on detection
302 of mutations in the *inhA* promoter. The sensitivity and specificity in detecting ETH
303 resistance using pDST as the reference was 64.7% (95% CI: 55.6 – 72.8) and 98.2%
304 (95%CI: 93.8 – 99.5) respectively (Figure 2). Using WGS and limited to analysis of

305 the *inhA* promoter only the sensitivity was 97.6% (95% CI: 91.6 – 99.3) (Figure 3).
306 Using the composite reference, the sensitivity was 65.9% (95% CI: 57.1 – 73.6) and
307 specificity of 100% (Figure 3; Figure 4).

308

309

310 **Fluoroquinolones (FLQs)**

311 A total of 231 samples had available results for both the test and pDST for FLQ and
312 the sensitivity was 90.6% (95% CI: 81.0 – 95.6) (Figure 2). A total of 289 samples
313 had available results for both the test and WGS and the sensitivity was 95.1% (95%
314 CI: 86.5 – 98.3) (Figure 3). Using a composite reference, the sensitivity was 90.6%
315 (95% CI: 81.0 – 95.6) (Figure 4). The specificity was 100% against pDST, WGS and
316 the composite reference (Figure 2, Figure 3, Figure 4).

317

318 The ability of the MTB/XDR test to accurately predict low level of FLQ resistance
319 using sequencing as the reference test was 100% (Supplementary Table 3). The
320 distribution of these *gyrA* mutations were Ala90Val (66.7%; 10/15), Asp94Ala (20%;
321 3/15) and Ser91Pro (13.3%; 2/15) (Supplementary Table 3).

322

323 **Second-line Injectable drugs (AMK, KAN, CAP)**

324 A total of 228 samples had available results for both MTB/XDR and AMK pDST while
325 it was lower for KAN (n=166) and CAP (n=167). The sensitivity in detecting
326 resistance to AMK, KAN and CAP using pDST as the reference were 96.2% (95%CI:
327 87.0 – 98.9); 84.6% (95%CI: 66.5 – 99.3) and 84.0 (95%CI: 65.3 - 93.6), respectively
328 (Figure 2). The respective sensitivities were higher using WGS as the reference:
329 98.0% (95%CI: 89.7 - 99.7) for AMK, 98.1% (95%CI: 89.9 - 99.7) for KAN and
330 98.0% (95%CI: 89.5 - 99.7) for CAP (Figure 3). Using the composite reference, the
331 sensitivity was 96.2% (95%CI: 87.0 – 98.9) for AMK, 92.7% (95%CI: 82.7 – 97.1) for
332 KAN and 92.5% (95% CI:82.1 – 97.0) for CAP (Figure 4). All SLIDs had a specificity
333 of 100% for pDST, sequencing and the composite reference test.

334

335 The ability of the MTB/XDR test to accurately predict resistance to the different
336 SLIDs were 100% for each of the anti-TB drugs, with cross-resistance between the
337 SLIDs predicted by the A1401G mutation in the *rrs* gene (Data not shown).
338 Additionally, resistance to KAN only was predicted by the C-12T mutation in the *eis*

339 promoter with resistance to both KAN and AMK predicted by the C-14T mutation in
340 the *eis* promoter (Data not shown).

341

342

343

344 **Discrepant result resolution**

345 A total of 74 discrepant results were identified between the MTB/XDR test and
346 pDST, with 70 false negative and 4 false positive results identified across all drugs
347 tested (Figure 2).

348

349 Four out of four (100%) of the false positive results were resolved by WGS that
350 identified mutations predicting INH and ETH resistance, indicating that the initial
351 susceptible pDST result for both INH and ETH were incorrect.

352

353 Sixty-four out of seventy false negative results (91.4%) were resolved by WGS that
354 showed the absence of target gene mutations predicting resistance to INH, FLQ,
355 SLIDs and ETH, indicating that the initial resistant pDST result obtained for the drug
356 targets were likely incorrect in these specimens. The false negative results in six
357 specimens (8.6%) were not resolved by WGS, and the cause of the discrepancy was
358 further investigated. One specimen that was identified as INH resistant by pDST, but
359 INH susceptible by the MTB/XDR test, showed the presence of a Leu203Leu *fabG1*
360 mutation that was not identified by the MTB/XDR test. Three specimens that were
361 identified as FLQ resistant by pDST, but FLQ susceptible by the MTB/XDR test
362 showed the presence of a Asp94Gly (n=2) and Ala90Val mutation (n=1) in the *gyrA*
363 gene. One specimen that was identified as KAN, AMK and CAP resistant by pDST,
364 but susceptible by MTB/XDR showed the presence of a A1401G mutation in the *rrs*
365 gene. Further investigation confirmed heteroresistance, however, the *rrs* mutant melt
366 peak was below the detection threshold of the MTB/XDR test and therefore reported
367 as KAN, AMK and CAP susceptible. Lastly, one specimen identified by the
368 MTB/XDR test as ETH susceptible, but resistant by pDST, had a G-17T mutation in
369 the *inhA* promoter region, which was initially missed by the MTB/XDR test.

370

371 A total of 11 discrepant results were identified between the MTB/XDR test and
372 sequencing, with 10 false negative results and 1 false positive result identified

373 (Figure 3). One false positive result was identified with the MTB/XDR test reporting
374 an INH resistant result and sequencing showing an INH susceptible result, although
375 this specimen showed a C-52A mutation in the *ahpC* region, which was not
376 considered associated with INH resistance by the study site.

377
378 Out of the 10 false negative results, one specimen was identified as INH susceptible
379 by MTB/XDR test but had a *fabG1* mutation identified by sequencing. Further
380 investigation failed to identify a root cause of the discrepancy, thereby indicating that
381 the MTB/XDR test incorrectly reported this specimen as INH susceptible. The
382 second specimen was incorrectly processed, and no INH resistance causing
383 mutation was identified upon resequencing. Three specimens, identified by the
384 MTB/XDR test as FLQ susceptible, was identified as FLQ resistant by sequencing
385 with the detection of Asp94Gly (n=2) and both Asp94Gly and Asp94Asn (n=1)
386 mutations in the *gyrA* gene. The *gyrA* double mutation of Asp94Gly and Asp94Asn
387 was below the detection threshold of the MTB/XDR test due to hetero-resistant
388 populations and was therefore not identified as FLQ resistance by the test. AMK,
389 KAN and CAP resistance was not detected by the MTB/XDR test in one specimen
390 since the A1401G *rrs* mutant peak was below the detection threshold of the test.
391 Lastly, ETH resistance was not detected by the MTB/XDR test in one specimen due
392 to a mixed culture and in a second specimen due to a specimen swop that showed
393 no *inhA* promoter mutation upon re-sequencing.

394

395 **Discussion**

396

397 The demonstrated diagnostic performance of the MTB/XDR test for *M. tuberculosis*
398 detection met the overall sensitivity ($\geq 80\%$) and specificity ($\geq 98\%$) requirements
399 relative to culture as outlined in the guidance for next-generation DST by the WHO
400 (16), with a 98.3% sensitivity and specificity of 100% specificity observed in the
401 current study. The diagnostic performance of the MTB/XDR test was comparable to
402 Ultra (pooled sensitivity 90.9% (95%CI: 86.2 – 94.7)); pooled specificity 95.6%
403 (95%CI: 93.0 – 97.4)) and G4 test (pooled sensitivity of 84.7% (78.6 – 89.9)) and
404 pooled specificity of 98.4% (95%CI: 97.0 – 99.3) as previously described (17). This
405 was also seen in the current study with high levels of agreement between the
406 MTB/XDR and the G4 and Ultra. This can be attributed to the similar limit of

407 detection (LoD) of the MTB/XDR (71.9 CFU/mL (95%CI: 58 to 100)) compared to the
408 G4 (86.9 CFU/mL (95%CI (72 to 110)) (10). The LoD of Ultra (15.6 CFU/mL),
409 however, is lower than that of MTB/XDR (11). Interestingly, the diagnostic sensitivity
410 of the MTB/XDR test in culture positive, smear negative specimens (94.7%) was
411 better than in Ultra (pooled sensitivity of 77.5% (95%CI: 67.6 to 85.6)) and G4
412 (pooled sensitivity of 60.6% (95%CI: 48.4 to 71.7)) as previously described (17). This
413 indicates that although the MTB/XDR test is a reflex test to be used in *M.*
414 *tuberculosis* positive cases (excluding 'Trace'), its ability to accurately detect *M.*
415 *tuberculosis* in sputum specimens is on par with Ultra and G4. Further studies on
416 processing specimens with MTB 'Trace' detected by Ultra which are expected to be
417 lower than the LoD of MTB/XDR and are for reflex testing is required. The MTB/XDR
418 test was able to successfully detect more than 98% of MTB samples detected by the
419 G4 (98.8%) and ULTRA (99.5%) tests, with each comparator test failing to detect
420 one sample each. These were both smear negative and in the case of ULTRA a
421 trace result. These finding are supportive of using the MTB/XDR test as a reflex
422 using the MTB/RIF tests as an indicator for the follow-on testing.

423

424 The clinical performance of the MTB/XDR test performance demonstrated by the
425 current study is similar to previous studies (18, 19) with sensitivity of >84% observed
426 for INH, SLIDs and FLQ relative to pDST. The sensitivity for predicting resistance to
427 INH, FLQ and AMK also met the minimum requirement of the target product profile
428 for next-generation pDST (sensitivity of >90% for INH, FLQ and sensitivity of ≥80%
429 for AMK) as specified by the WHO (9, 16). In contrast, lower sensitivity of the MTB
430 XDR test in predicting ETH resistance (sensitivity of 64.7% (95%CI: 55.6 – 72.8))
431 compared to pDST was demonstrated in the current study, with sensitivity estimates
432 comparable to previously published studies (18, 19). This is due to the inclusion of
433 only the *inhA* promoter target as a proxy for ETH resistance in the MTB/XDR test,
434 since mutations in additional targets (e.g. *ethA*) have been identified to confer
435 resistance to ETH in clinical specimen from TB patients (20, 21).

436

437 When considering sequencing alone, the clinical performance of the MTB/XDR
438 assay for all drug targets increased to >95% sensitivity and >99% specificity (Figure
439 3). The lowest sensitivity was observed for FLQ (95.1%) due to the presence of
440 heteroresistant *gyrA* populations in each of these isolates which were below the limit

441 of detection in the clinical specimen. Similarly, the A1401G (*rrs*) mutation was
442 identified but at a level below detection of the MTB/XDR assay. The overall
443 sensitivities showed a slight decrease for most drugs and an expected significant
444 decrease for ETH with specificities remaining at >99% against the composite
445 reference standard (Figure 4). Sensitivities of >90% were observed for INH and
446 FLQ, >92% for KAN and CAP, and >96% for AMK which meet the minimum criteria
447 for the target product profile for next generation DST assays. The lower sensitivity of
448 65.9% (95%CI: 57.1-73.6) observed for ETH compared to 97.6% relative to
449 sequencing, was suggestive of the presence of additional mutations in targets not
450 covered by the assay or false ETH resistance on phenotypic DST. The latter cannot
451 be confirmed since pDST was not performed for discordant results, however ETH
452 pDST is known to be unreliable (22). Based on these findings ETH resistance can
453 be ruled in and not ruled out using the MTB/XDR assay, in agreement with previous
454 observations (23).

455

456 Overall, the sensitivities observed for the composite reference were comparable to
457 those previously reported in a geographically diverse setting for INH (90.1% vs
458 94.0%) and FLQ (90.6% vs 94%) and higher for AMK (96.2% vs 73.0%), KAN
459 (92.7% vs 86.0%), CAP (92.5% vs 61.0%) and ETH (65.9% vs 54.0%) (23). The
460 improved sensitivities highlight the accuracy of the assay in predicting resistance,
461 particularly for INH, FLQ, AMK, KAN and CAP, in our setting. The higher
462 performance observed when using sequencing as a reference is due to evaluation of
463 the regions targeted by the assay only and not considering all resistance conferring
464 mutations across the genome. Further, due to the restricted analysis for sequencing,
465 the discordance observed between phenotypic susceptibility testing and the
466 MTB/XDR test could not be resolved.

467

468 The performance of the Xpert XDR in our study for INH resistance detection relative
469 to pDST was similar to the GenoType MTBDRplus 90.7% (95% CI: 84.8 – 94.5) vs
470 93% (95% CI: 90 – 95) for INH, however, sensitivity for FLQ resistance detection
471 was lower than the GenoType MTBDRsl 90.6% (95%CI: 81.0 – 95.6) vs 95%
472 (95%CI: 91 - 97) (ref 20). When considering performance relative to sequencing,
473 resistance detection by Xpert XDR for INH was superior to the GenoType

474 MTBDRplus 98.5% (95%CI: 94.6 – 99.6) and equivalent to GenoType MTBDRsl for
475 FLQ 95.1 (95%CI: 86.5 – 98.3).

476

477 Two shorter standardized regimens for DR-TB are currently recommended by WHO:
478 a regimen for MDR/RR-TB where the injectable agent has been replaced by BDQ
479 (used for 6 months), in combination with levofloxacin (LFX)/moxifloxacin (MXF),
480 ethionamide (ETH), EMB, high-dose INH, PZA and CFZ for 4 months in the
481 intensive phase; and a 6-month regimen for that includes the new anti-TB agent, Pa,
482 which was also recommended by WHO in 2020 for use under operational research
483 conditions, in combination with BDQ and LZD (24). LPAs have been recommended
484 by the WHO for the detection of *Mycobacterium tuberculosis* (*M. tuberculosis*) strains
485 resistant to rifampicin, in both smear positive and smear negative sputum specimens
486 (25, 26). Currently, these LPAs are being used at-scale in South Africa, however,
487 delayed result reporting is a common problem experienced with routine use mainly
488 due to technical aspects such as sample batching. Another challenge with LPAs is
489 its poor sensitivity on smear negative specimens that require repeat testing on
490 cultured isolates. In a recent study, done at two sites in South Africa the median time
491 to LPA results ranged between 5.4 – 23.1 days (27). These delays negatively impact
492 TB control, allowing for the continued transmission of drug resistant *M. tuberculosis*. The test is
493 capable of determining level of resistance for both INH and FLQ based on the
494 interpretation of melt-curves detecting the presence of associated mutations. This
495 allows for supporting clinical management by making available the use of both high-
496 dose INH and MFX for patient management, particularly patients requiring a salvage
497 regimen. *tuberculosis* strains and result in inadequate management of patients.
498 Alternative assays providing the same information are still not readily available. Next-
499 generation sequencing-based technologies show early promise, however, none have
500 matured sufficiently to an end-to-end *in vitro* diagnostic assay ready for routine use.

501

502 The NHLS is a key partner of the National TB Program and adapts to having the
503 latest and most sensitive diagnostic capability to further strengthen the program.
504 South Africa was the first country to implement the GeneXpert MTB/RIF and
505 GeneXpert MTB/RIF Ultra assay, at scale, as a smear microscopy replacement
506 technology in 2011 and one of the first to perform susceptibility testing for new and
507 repurposed anti-TB drugs (Bedaquiline and Linezolid) as part of diagnosis. Further

508 diagnosis was improved, particularly in HIV co-infected TB-disease individuals,
509 through replacement of GeneXpert MTB/RIF assay with the Xpert MTB/RIF Ultra
510 assay in 2017 with South Africa again taking the lead. These efforts have aided in
511 improved management of people diagnosed with TB and drug-resistant TB, thereby
512 reducing South Africa's burden of disease.

513

514 NHLS has fully implemented this technology following of the WHO recommendation
515 to strengthen the detection and management of drug-resistant TB, an emerging
516 global threat. The deployment of the assay leverages the existing instrument network
517 and testing capacity, increases utilization and thereby maximizes efficiency. The
518 potential benefits are a reduction in public health expenditure, a reduction in the
519 number of repeat tests (through the traditional testing modalities) and a significantly
520 improved turnaround time. Ultimately, turnaround time improvements benefit those
521 individuals' requiring treatment by enabling clinicians to take earlier appropriate
522 management decisions impacting treatment outcomes.

523

524

525 **ACKNOWLEDGEMENTS**

526

527 We thank the study investigators, clinical research coordinators, and laboratory staff
528 at the Centre for Tuberculosis, NICD/NHLS for their diligent efforts.


529 The study sponsor (Cepheid) provided the investigational product, funding and
530 administrative and logistical support to this study site. The sponsor was involved in
531 the design, conduct and execution of the clinical study, and assisted in monitoring
532 and collection of data. The sponsor participated in the interpretation of the data and
533 preparation of the manuscript. GL and XL are Cepheid employees.

534 SVO, LJ, FI, DN, TG, MvdM collected the data and performed the experiments. XL
535 performed the statistical analysis. SVO and GL drafted the manuscript. All authors
536 reviewed and critiqued the draft manuscript and approved the final manuscript prior
537 to submission for publication.

538

539

540 **Tables & Figures**



541

542

543 **Figure 1.** Flowchart illustrating the diagnostic characteristics of the sediments.

544 MTB/RIF POSITIVE constitutes MTB Detected; MTB/RIF Ultra POSITIVE constitutes MTB Detected Very Low,
545 MTB Detected Low, MTB Detected Medium, MTB Detected High; MTB/RIF Ultra TRACE constitutes MTB Trace
546 Detected; MTB/RIF or MTB/RIF Ultra NEGATIVE constitutes MTB Not Detected; RIF RES indicates Rifampicin
547 Resistant, RIF SENS indicates Rifampicin Sensitive, RIF IND indicates Rifampicin Indeterminate.

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563 **Table 1:** Demographics and diagnostic characteristics of specimens included in the analysis

	Overall (N=322)
Demographic Characteristics	
Sex	
Female	148 (46.0%)
Male	162 (50.3%)
N/A	12 (3.7%)
Age (Years)	
Median [Min, Max]	37 (13-85)
MGIT culture / AFB smear	
% Culture positive [n/N]	92.2% [297/322]
% smear positive [n/N]	74.4% [221/297]
% smear negative [n/N]	25.6% [76/297]
% Culture negative [n/N]	7.8% [25/322]
G4	
%G4 results [n/N]	31.1% [100/322]
% Positive ^a [n/N]	86.0% [86/100]
% RIF RES ^d [n/N]	74.4% [64/86]
% RIF SENS ^e [n/N]	25.6% [22/86]
% Negative ^c [n/N]	14.0% [14/100]
Ultra	
% Ultra results [n/N]	68.9% [222/322]
% Positive ^b [n/N]	91.9% [204/222]
% RIF RES ^e [n/N]	30.4% [62/204]
% RIF SENS ^f [n/N]	68.6% [140/204]
% RIF IND ^g [n/N]	1.0% [2/204]
%Trace ^d [n/N]	1.8% [4/222]
RIF IND ^g [n/N]	100% [4/4]
% Negative ^c [n/N]	6.3% [14/222]

564 ^aG4 Positive constitutes MTB Detected

565 ^bUltra Positive constitutes MTB Detected Very Low, MTB Detected Low, MTB Detected Medium, MTB Detected High

567 ^cG4 or Ultra Negative constitutes MTB Not Detected

568 ^dUltra Trace constitutes MTB Trace Detected

569 ^eRIF RES indicates Rifampicin Resistant

570 ^fRIF SENS indicates Rifampicin Sensitive

571 ^gRIF IND indicates Rifampicin Indeterminate

572

573

574


575 **Table 2:** Performance summary of the MTB/XDR test relative to MGIT culture, G4 and Ultra test for
576 *M. tuberculosis* detection.

	Sensitivity/PPA (95% CI)	Specificity/NPA (95% CI)
MGIT Culture^a		
Overall	98.3% (96.1 – 99.3)	100% (86.7 – 100)
Culture positive, Smear positive	99.5% (97.5 – 99.9)	N/A
Culture positive, Smear negative	94.7% (87.2 – 97.9)	N/A
G4^b	98.8% (95%CI: 93.7-99.8)	100.0% (95%CI: 78.5-100.0)
Ultra^b	99.5% (95%CI: 97.3-99.9)	100.0% (95%CI: 78.5-100.0)

577 ^a Diagnostic Performance of MTB/XDR test in *M. tuberculosis* detection relative to MGIT culture was assessed by
578 sensitivity and specificity.


579 ^b Diagnostic performance of MTB/XDR test in *M. tuberculosis* detection relative to G4 and Ultra was assessed by
580 PPA and NPA.

581
582




583 **Figure 2:** Performance of the MTB/XDR test in predicting resistance to INH, FLQ, AMK, KAN, CAP,
584 ETH relative to pDST. TP -True Positive, FN – False Negative; TN – True Negative; FP – False
585 Positive; Sens. – Sensitivity; Spec.- Specificity
586

587
588



589 **Figure 3:** Performance of the MTB/XDR test in detection of resistance to INH, FLQ, AMK, KAN, CAP,
590 ETH relative to sequencing. TP -True Positive, FN – False Negative; TN – True Negative; FP – False
591 Positive; Sens. – Sensitivity; Spec.- Specificity
592

593



594

595

Figure 4: Performance of the MTB/XDR test in detection of resistance to INH, FLQ, AMK, KAN, CAP, ETH relative to the composite test. TP -True Positive, FN – False Negative; TN – True Negative; FP – False Positive; Sens. – Sensitivity; Spec.- Specificity

597

598

599

600

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635 **SUPPLEMENTARY DATA**

636

637 **Supplementary Table 1:** Performance of MTB/XDR test compared to MGIT Culture stratified by

638 smear status

		Culture				
		Positive			Negative	Total
		Smear +	Smear -	Overall Culture +	Overall Culture -	
MTB/XDR Test	MTB Detected	220	72	292	0	292
	MTB Not Detected	1	4	5	25	30
	Total	221	76	297	25	322
Performance in Culture Positive Smear Positive group: Sensitivity: 99.5% (220/221), 95% CI: 97.5, 99.9 Performance in Culture Positive Smear Negative group: Sensitivity: 94.7% (72/76), 95% CI: 87.2, 97.9 Performance Overall: Sensitivity: 98.3% (292/297), 95% CI: 96.1, 99.3 Specificity: 100% (25/25), 95% CI: 86.7, 100						

639

640

641 **Supplementary Table 2:** Low Level INH resistance prediction by MTB/XDR test relative to *inhA*

642 promoter mutations identified by sequencing

	INH		Total
	C-15T (<i>inhA</i> promoter)	T-8C (<i>inhA</i> promoter)	
Low Level INH Resistance Detected by MTB/XDR test	23	1	24
Total	23 (95.8%)	1 (4.2%)	24 (100%)

643

644 **Supplementary Table 3:** Low level FLQ resistance prediction by MTB/XDR test relative to *gyrA*

645 mutations identified by sequencing

	FLQ			Total
	Ala90Val (<i>gyrA</i>)	Asp94Ala (<i>gyrA</i>)	Ser91Pro (<i>gyrA</i>)	
Low Level FLQ Resistance Detected by MTB/XDR test	10	3	2	15
Total	10 (66.7%)	3 (20.0%)	2 (13.3%)	15 (100.0%)

646

647 **References:**

648

649 1. World Health Organization. 2023. Global tuberculosis report 2023. Geneva:

650 World Health Organization; 2023. Licence: CC BY-NC-SA 3.0 IGO. World

651 Health Organization.

652 2. Pai M, Dewan PK, Swaminathan S. 2023. Transforming tuberculosis

653 diagnosis. Nat Microbiol 8:756–759.

654 3. World Health Organization. 2021. Global tuberculosis report 2021. Geneva:

655 World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. World

656 Health Organization.

657 4. World Health Organization. 2022. Global tuberculosis report 2022. Geneva:

658 World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO. World

659 Health Organization.

660 5. World Health Organization. 2022. Implementing the end TB strategy: the

661 essentials, 2022 update. Geneva: World Health Organization; 2022. Licence:

662 CC BY-NC-SA 3.0 IGO. World Health Organization.

663 6. WHO. 2021. WHO consolidated guidelines on tuberculosis. Module 3:

664 diagnosis - rapid diagnostics for tuberculosis detection, 2021 update. Geneva:

665 World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. World

666 Health Organization.

667 7. Iruedo J, O'Mahony D, Mabunda S, Wright G, Cawe B. 2017. The effect of

668 the Xpert MTB/RIF test on the time to MDR-TB treatment initiation in a rural

- 669 setting: a cohort study in South Africa's Eastern Cape Province. BMC Infect
670 Dis 17:91.
- 671 8. Naidoo P, Toit E, Dunbar R, Lombard C, Caldwell J, Detjen A. 2014. A
672 Comparison of Multidrug-Resistant Tuberculosis Treatment Commencement
673 Times in MDRTBPlus Line Probe Assay and Xpert MTB/RIF-Based
674 Algorithms in a Routine Operational Setting in Cape Town. PLoS ONE.
- 675 9. World Health Organization. 2014. Meeting report: High-priority target product
676 profiles for new tuberculosis diagnostics: report of a consensus meeting;
677 World Health Organization (2014). (WHO/HTM/TB/2014.18). World Health
678 Organization.
- 679 10. Cao Y, Parmar H, Gaur RL, Lieu D, Raghunath S, Via N, Battaglia S, Cirillo
680 DM, Denkinger C, Georghiou S, Kwiatkowski R, Persing D, Alland D,
681 Chakravorty S. 2020. Xpert MTB/XDR: A ten-color reflex assay suitable for
682 point of care settings to detect isoniazid-, fluoroquinolone-, and second line
683 injectable drug-resistance directly from *Mycobacterium tuberculosis* positive
684 sputum. BioRxiv <https://doi.org/10.1101/2020.09.08.288787>.
- 685 11. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, Banada
686 PP, Deshpande S, Shenai S, Gall A, Glass J, Krieswirth B, Schumacher SG,
687 Nabeta P, Tukvadze N, Rodrigues C, Skrahina A, Tagliani E, Cirillo DM,
688 Davidow A, Denkinger CM, Persing D, Kwiatkowski R, Jones M, Alland D.
689 2017. The New Xpert MTB/RIF Ultra: Improving Detection of *Mycobacterium*
690 tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-
691 Care Testing. MBio 8.

- 692 12. Global Laboratory Initiative. 2014. Mycobacteriology Laboratory Manual. First
693 Edition, April 2014. Stop TB Partnership.
- 694 13. Rüsç-Gerdes S, Pfyffer GE, Casal M, Chadwick M, Siddiqi S. 2006.
695 Multicenter laboratory validation of the BACTEC MGIT 960 technique for
696 testing susceptibilities of Mycobacterium tuberculosis to classical second-line
697 drugs and newer antimicrobials. J Clin Microbiol 44:688–692.
- 698 14. World Health Organization. 2018. Technical Report on critical concentrations
699 for drug susceptibility testing of medicines used in the treatment of drug-
700 resistant tuberculosis. Geneva: World Health Organization; 2018
701 (WHO/CDS/TB/2018.5). Licence: CC BY-NC-SA 3.0 IGO. . World Health
702 Orgaization.
- 703 15. Ismail NA, Ismail F, Joseph L, Govender N, Blows L, Kaniga K, Omar SV.
704 2020. Epidemiological cut-offs for Sensititre susceptibility testing of
705 Mycobacterium tuberculosis: interpretive criteria cross validated with whole
706 genome sequencing. Sci Rep 10:1013.
- 707 16. World Health Organization. 2021. Target product profile for next-generation
708 drug-susceptibility testing at peripheral centres. Geneva: World Health
709 Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. World Health
710 Organization.
- 711 17. Zifodya JS, Kreniske JS, Schiller I, Kohli M, Dendukuri N, Schumacher SG,
712 Ochodo EA, Haraka F, Zwerling AA, Pai M, Steingart KR, Horne DJ. 2021.
713 Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin

- 714 resistance in adults with presumptive pulmonary tuberculosis. Cochrane
715 Database Syst Rev 2:CD009593.
- 716 18. Truden S, Sodja E, Žolnir-Dovč M. 2023. Drug-Resistant Tuberculosis on the
717 Balkan Peninsula: Determination of Drug Resistance Mechanisms with Xpert
718 MTB/XDR and Whole-Genome Sequencing Analysis. *Microbiol Spectr*
719 11:e0276122.
- 720 19. Katamba A, Ssengooba W, Sserubiri J, Semugenze D, William KG, Abdunoor
721 N, Byaruhanga R, Turyahabwe S, Joloba ML. 2023. Evaluation of Xpert ®
722 MTB/XDR test for susceptibility testing of Mycobacterium tuberculosis to first
723 and second-line drugs in Uganda. medRxiv
724 <https://doi.org/10.1101/2023.04.03.23288099>.
- 725 20. Vilchèze C, Jacobs WR. 2014. Resistance to Isoniazid and Ethionamide in
726 Mycobacterium tuberculosis: Genes, Mutations, and Causalities. *Microbiol*
727 *Spectr* 2.
- 728 21. World Health Organization. 2021. Catalogue of mutations in Mycobacterium
729 tuberculosis complex and their associatoin with drug resistance. Geneva:
730 World Health Organization; 2021. Licence: CC BY-NC-SA 3.0 IGO. World
731 Health Organization.
- 732 22. Varma-Basil M, Prasad R. 2015. Dilemmas with ethionamide susceptibility
733 testing of Mycobacterium tuberculosis: A microbiologist & physician's
734 nightmare. *Indian J Med Res* 142:512–514.

- 735 23. Penn-Nicholson A, Georghiou SB, Ciobanu N, Kazi M, Bhalla M, David A,
736 Conradie F, Ruhwald M, Crudu V, Rodrigues C, Myneedu VP, Scott L,
737 Denkinger CM, Schumacher SG, Xpert XDR Trial Consortium. 2021. Clinical
738 evaluation of the Xpert MTB/XDR assay for rapid detection of isoniazid,
739 fluoroquinolone, ethionamide and second-line drug resistance: A cross-
740 sectional multicentre diagnostic accuracy study. medRxiv
741 <https://doi.org/10.1101/2021.05.06.21256505>.
- 742 24. Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N,
743 Samoilova A, Skornykova S, Tudor E, Variava E, Yablonskiy P, Everitt D,
744 Wills GH, Sun E, Olugbosi M, Egizi E, Li M, Holsta A, Timm J, Bateson A,
745 Crook AM, Fabiane SM, Hunt R, McHugh TD, Tweed CD, Foraida S, Mendel
746 CM, Spigelman M, ZeNix Trial Team. 2022. Bedaquiline-Pretomanid-Linezolid
747 Regimens for Drug-Resistant Tuberculosis. *N Engl J Med* 387:810–823.
- 748 25. World Health Organization. 2016. The use of molecular line probe assay for
749 the detection of resistance to isoniazid and rifampicin: policy update. World
750 Health Organization.
- 751 26. World Health Organization. 2016. The use of molecular line probe assays for
752 the detection of resistance to second-line anti-tuberculosis drugs. Policy
753 guidance . World Health Organization.
- 754 27. Centner C, Dolby T, Hayes C, Zemanay W, Brown P, Munir R, David A, Rieß
755 F, Nicol M, Brink A, Tagliani E, Cirillo D, Ruhwald M, Scott L, Cox H, Penn-
756 Nicholson A. 2022. Reflex commercial second-line genotypic susceptibility
757 testing of residual rifampicin-resistant sputum specimens: a two-site

758 diagnostic laboratory-based feasibility study in South Africa. 4d. Molecular
759 diagnostics (including POCT and syndromic testing). P1078. ECCMID.
760